Holen Sie sich die Stockscreener-App
24.00
5.67%
0.35
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Transcript : Vera Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03 - marketscreener.com
Vera Therapeutics (VERA) Sees Surge in Bullish Options Activity | VERA Stock News - GuruFocus
Vera Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Expands Team with 17 New Hires, Awards Major Stock Options Worth $6M - Stock Titan
H.C. Wainwright maintains $85 target on Vera Therapeutics stock By Investing.com - Investing.com Canada
Wedbush Cuts Price Target on Vera Therapeutics to $23 From $32, Keeps Neutral Rating - marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP - Defense World
California State Teachers Retirement System Acquires 6,749 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down – Should You Sell? - Defense World
Biotech Stocks To Watch Today – June 6th - Defense World
Otsuka’s IgAN Data Top Some Vera Results, But To What End? - insights.citeline.com
Vera Therapeutics (VERA) Drops 32% After Trial Results Disappoin - GuruFocus
Vera Therapeutics (VERA) Stock Plummets Over 29% in Major Sell-Off - Daily Chhattisgarh News
Biotech Stock Vera Is Slumping After Monster Gain - Barron's
Vera Therapeutics stock sinks following competitor’s successful trial By Investing.com - Investing.com Nigeria
Vera Therapeutics stock sinks following competitor’s successful trial - Investing.com Australia
Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ) - Seeking Alpha
Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Research Analysts Offer Predictions for VERA FY2027 Earnings - Defense World
IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Scotiabank Increases the Price Target for Vera Therapeutics by $10 - MSN
FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World
(VERA) Trading Advice - news.stocktradersdaily.com
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN
Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan
Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire
Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World
Vera Therapeutics eyes half billion dollars after kidney drug study - The Business Journals
Vera Therapeutics (VERA) Price Target Increased Amid Positive Tr - GuruFocus
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India
Vera Therapeutics (VERA) Secures $500 Million Credit Facility - GuruFocus
Vera Therapeutics (VERA) Sees Price Target Boost Following Positive Trial Results | VERA Stock News - GuruFocus
Vera Therapeutics Secures $500M Loan Agreement - TipRanks
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph
Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan
Two Sigma Investments LP Sells 7,102 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) PT Set at $65.00 by Scotiabank - Defense World
Vera Therapeutics (NASDAQ:VERA) Given New $85.00 Price Target at HC Wainwright - Defense World
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo Finance
These 10 Stocks Blew Past Expectations - Insider Monkey
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade - Defense World
Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks
H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks
Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment - TipRanks
Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment - TipRanks
Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN - insights.citeline.com
Vera Therapeutics (VERA) Surges 67.49% After Landmark Phase 3 Trial Results - Wealth Daily
Evercore ISI maintains outperform rating on Vera Therapeutics stock By Investing.com - Investing.com South Africa
Scotiabank Maintains Sector Outperform Rating for Vera Therapeutics (VERA) | VERA Stock News - GuruFocus
Vera rises after success in late-stage trial for IgA nephropathy treatment - Seeking Alpha
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Benzinga
Wedbush Raises Price Target on Vera Therapeutics to $32 From $26, Maintains Neutral Rating - marketscreener.com
Scotiabank Increases Vera Therapeutics (VERA) Price Target to $6 - GuruFocus
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):